for today. everyone Good and thank afternoon, Hannah. you, joining us you Thank
company’s update slides quarterly to the happy then the During today’s Q&A. I ‘XX remarks, with towards business business ‘XX to call the will will to strategy. for quarter our support the our begin our the our turn I open over we call financials focusing XX will fourth and on a guidance. year be progress before After Vision with to will full Tom of discuss commentary. I then call, prepared and up use concluding ending Tom
‘XX, Vision vision strategy have in a XXXX. X-year ‘XX remain of XX. significant December driven three-pillar that we This progress called made our which growth in we will that In is focus we by a strategy communicated on
market adoption. The first increasing pillar leadership new through focus subcutaneous position is expanding label patient on a SCIg immunoglobulin, pre-fill in driving and our growing indications, our or a starts
in in therapies. expanding current new large position delivery Second we to volume the business is drug leadership novel our home the drugs, call
three Finally, into international pillars expanding Supporting our innovation, both foundation and regulatory these businesses rooted expertise a and growth markets. in excellence. operational of is quality
an our key in Vision the Vision has advanced to XXXX strategy year a position we drug commitments strengthen XX as a several growth milestones a our on tremendous XX accelerate revenues specific TAM solutions to business our in core through expansion by with XX% revenue novel therapies transforming delivery strategy drug by the ‘XX. revenue approximately will grow partner business This business. be an and our to CAGR to Ig a accomplished reaching million as in home. and with focuses in investment double-digits $XX player and leader been a broad delivery from through
commercialized to new and five one delivery Phase new Within indication. drug drug business, X committed trials collaborations would signing this therapies that multiple novel to we lead
X to and/or a new committed we indications billion addition, In and TAM. products $X.X XXX(k)
milestones. investments against at a these in our innovation, I Lastly, we am XXXX, investment proud and commercial disciplined year our to aimed doing committed very strategy progress this of key strengthening foundation. with our first
our our U.S. quarter saw growth has marking international core been our core growth the pipeline associated part across strength transformational increase as our there. the of in more market we saw increased double-digit therapies double-digit revenue the of our of We addressable The growth double-digit growth market. our back we novel portfolio in and half focus including We and total XX%, posted business fifth in year-over-year consecutive outperforming growth. the
of Novel importantly, our progressed total year-over-year X with subcu Apellis’ a broader revenues. EMPAVELI a of outside categories, XX the confidence has commercial total by $X.X total U.S. was these well in and pipeline included driver X in us We of potential therapies of drug to billion X Aspaveli ‘XX market Phase the collaborations excess to This one indication. addressable new XX movement then key or commercial ‘XX our the target the launch, our in drug to-date across doubled collaboration target. of one total ended collaborations trials to delivery our $X.X the our drug a exceeding The give Most supporting collaborations target that of home. through billion
this areas: $XX.X this needed a and doing support focused investments from growth. on quarter third and to the and management did three an committed year, disciplined investment the cash the development ahead a of million, executed expanding with diligent move to while cash keeping while $XX investing foundation ending with business our an We capabilities, guidance innovation new increase commercialization all eye with of million. also our our and our We where year of with to We increasing in strategy. stronger majority of efforts, facilities. building This we a
We year significant clear strides our XX milestones. ‘XX over-performing of towards first Vision progress the our have with made towards plan, in
second interruption on the business, we the quarters. XX% in third in leadership We market. focused our In outperformed underlying our U.S. the a growing position drug market growth and SCIg growing despite supply
We our which a for to strive of success market we have marker as outperform. target drug a growth used and the underlying
the X% drug year growth grew up in market ‘XX, from For ‘XX. the SCI X%, full
in and reported script roughly are We and the XX%. market the drug growth year, SCIg growth excited positive momentum fourth by including quarter of the market XX% overall of
the the Freedom accounting it in to have we the patient with revenues, lag one quarter get generally we takes to home. for As timing communicated, timing system script KORU the the our a see from operational
are of total of quarter fourth in by growing outpacing and patients growth At on home, start and therapy are drug as now we the therapy XX% strong script market is ‘XX, therapy. IVIg the anticipate We subcu the trend representing drug to ‘XX. excited SCIg end
New non-Ig And positioned on-label have the and a the EMPAVELI. in focus indications X has we remain patients we syringes core with to new part Increasing for primary indications remain are broadest different X XX with will year continue months, capitalize To-date, company. this Medical starts one KORU uniquely Grifols and with for the the Ig, partners. be patients on past to X our to pre-filled starts Octapharma of labels and on-label a patient with one for new added In label Apellis’ a indications new strategy. on-label for CSL market.
penetration finally, grow the total receiving for X% of with from clearance FreedomEdge approximately have the pre-fill FDA syringes market XX% ‘XX, in And quarter we of system with use since ‘XX, the market our roughly in November XX% seen our penetration. to pre-filled of fourth ending
growth this of doubling with tracked our pumps. FreedomEdge also We
syringes. We the this market through therapy for to the anticipate share future additional conversion in to capitalize still we near stages preference an continue to come in sizes, early to with of drive patient growth. supporting and increased market, well-positioned grow its to subcu third Although to ease-of-use pre-filled and PFS see indications about our and remain the and current opportunity syringe on a we pre-filled
in momentum, growth expand seen their distribution our efforts, growth business We year-over-year we have partners an core half internationally. currently accelerated impressive countries, immediate geographic as our our have driven pharma indications. focused In X% XX% as international expansion providing positive efforts over leverage we with our by in ex-U.S. second of and XX
As in plasma Ig in see shortages supply drug also ‘XX. ‘XX, a alleviate we growing ex-U.S.
our is starts international patient driver core business. of New an and essential both
drug to work with one pharma together Notably, we launches our relationships partners and capture saw deepen ‘XX, we continue further international increase to various markets to to opportunities launch, Aspaveli global in multiple across anticipate in efforts in ‘XX. geographic We the new countries. and
Our to distribution is our second focus area partnerships. strengthen
several key meaningful growth markets have representing identified opportunities. We
indicating efforts our double capture. EU sales have Our in seen new initial patient pump year-over-year, growth
the existing electronic system, reliability economic also and patient of base penetrate opportunity building are pumps an of advantages. in We comfort, new evidence device additional process the and benefits Freedom see the of the clinical for including to
has business, of Moving a marked to novel year exciting our progress. XXXX therapies
a indications that drug has the significantly in that Most growth to for our We will commercialized, opportunity pipeline short-term. have accompanying we future contributed the when grow solid importantly, created it substantially. creates business
commercial in core business support to Our part services revenues. NT generated consists the revenue trials a revenues When and drug prior launch. products non-recurring business launches, engineering of our drug’s of of revenues becomes and clinical in this
billion, new ‘XX $X.X now have aspirations. more X.X and more launch past opportunity, immunology transparency provided collaborations, Over detailed Xx patients collaborations roughly a quarters, include majority the including projected multiple new this created the which and pipeline roughly have on new quarter, across market including total, of view shared our million business In we dates. this our potential of we drug providing a core of this original in we opportunity, over XX our few areas. therapy and in TAM established The
We to our collaborations their are the pleased trusted the help and biopharma with the deliver execution increased on that drugs. us have companies engagement from
to team and We therapies to X we increasing milestones shift. X have and innovation research. large increasing clear timelines trials may may ‘XX. will of event become product feasibility on therapies, in Phase every upon in opportunities is opportunity. fail drug our they momentum our sales for build execute canceled, capabilities, forward leader novel a novel in our for Our to volume the at company’s agreements continuing consideration Due as clinical and the revenues the drugs nature Based and for look be
remain multiple total our collaborations to we in deals clear the a pipeline, sight of additional will opportunities XX. goals. ‘XX year collaborations, and line of ending believe includes candidates six Phase of This bringing X approximately an along pace our with with we new multiple and our we stable, working new on However, are to commercialization anticipate number relatively
year start strong a on announcement successful to ‘XX Vision in have execution strategy. syringe with a one, deal growth another of our first We ‘XX quarter pre-filled
our turn now Tom will to over to I the review results. call financial
